First-line therapy for T cell lymphomas: a retrospective
population-based analysis of 906 T cell lymphoma patients

J 2019

First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients

JANÍKOVÁ, Andrea, Renata CHLOUPKOVÁ, Vit CAMPR, Pavel KLENER, Jitka HAMOUZOVA et. al.

Basic information

Original name

First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients

Authors

JANÍKOVÁ, Andrea (203 Czech Republic, guarantor, belonging to the institution), Renata CHLOUPKOVÁ (203 Czech Republic, belonging to the institution), Vit CAMPR (203 Czech Republic), Pavel KLENER (203 Czech Republic), Jitka HAMOUZOVA (203 Czech Republic), David BELADA (203 Czech Republic), Vit PROCHAZKA (203 Czech Republic), Robert PYTLIK (203 Czech Republic), Jan PIRNOS (203 Czech Republic), Juraj DURAS (203 Czech Republic), Heidi MOCIKOVA (203 Czech Republic), Zbyněk BORTLÍČEK (203 Czech Republic, belonging to the institution), Natasa KOPALOVA (203 Czech Republic), Jiří MAYER (203 Czech Republic, belonging to the institution) and Marek TRNENY (203 Czech Republic)

Edition

Annals of hematology, New York, Springer Verlag, 2019, 0939-5555

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.904

RIV identification code

RIV/00216224:14110/19:00112767

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1007/s00277-019-03694-y

UT WoS

000475694100018

Keywords in English

T cell lymphoma; Auto-SCT; Etoposide; Prognosis

Abstract

V originále

Peripheral T cell lymphomas (PTLs) have a globally poor prognosis. The CHOP regimen shows insufficient efficacy; first-line consolidation with autologous stem cell transplantation (auto-SCT) is a promising strategy but has never been confirmed by randomized data. We analyzed retrospectively 906 patients diagnosed with PTL between 1999 and 2015. Chemotherapy was given to 862 patients, and 412 of them were <60years. In this subset, we compared induction with CHOP (n=113) vs. CHOEP (n=68) and tested auto-SCT (n=79) vs. no SCT (n=73) in the intent-to-treat analysis. The median age of the whole cohort at diagnosis was 60years (range; 18-91); the median follow-up was 4.3years (range; 0.1-17.8). A shorter overall survival (OS) was associated with the male gender, age >= 60years, stage III/IV, performance status >= 2, bulky tumor >= 10cm, and elevated LDH. CHOEP induction showed a better 5-year PFS (25.0% vs. 32.9%; p.001), and 5-year OS (65.6% vs. 47.6%; p.008) than CHOP. Auto-SCT compared to no SCT brought a 5-year OS of 49.2% vs. 59.5% (p.187). Auto-SCT did not influence the OS in low-risk or low-intermediate risk PTLs. The high-intermediate and high-risk IPIs displayed a worse 5-year OS in auto-SCT arm (17.7% vs.46.2%; p.049); however, 73.9% of the patients never received planned auto-SCT. Our population-based analysis showed the superiority of CHOEP over CHOP in first-line treatment. We confirm the 5-year OS of around 50% in PTLs undergoing auto-SCT. However, the intended auto-SCT could not be given in 73.9% of the high-risk PTLs.

Citovat

JANÍKOVÁ, Andrea, Renata CHLOUPKOVÁ, Vit CAMPR, Pavel KLENER, Jitka HAMOUZOVA, David BELADA, Vit PROCHAZKA, Robert PYTLIK, Jan PIRNOS, Juraj DURAS, Heidi MOCIKOVA, Zbyněk BORTLÍČEK, Natasa KOPALOVA, Jiří MAYER and Marek TRNENY. First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. Annals of hematology. New York: Springer Verlag, 2019, vol. 98, No 8, p. 1961-1972. ISSN 0939-5555. Available from: https://dx.doi.org/10.1007/s00277-019-03694-y.

@article{1611116,
   author = {Janíková, Andrea and Chloupková, Renata and Campr, Vit and Klener, Pavel and Hamouzova, Jitka and Belada, David and Prochazka, Vit and Pytlik, Robert and Pirnos, Jan and Duras, Juraj and Mocikova, Heidi and Bortlíček, Zbyněk and Kopalova, Natasa and Mayer, Jiří and Trneny, Marek},
   article_location = {New York},
   article_number = {8},
   doi = {http://dx.doi.org/10.1007/s00277-019-03694-y},
   keywords = {T cell lymphoma; Auto-SCT; Etoposide; Prognosis},
   language = {eng},
   issn = {0939-5555},
   journal = {Annals of hematology},
   title = {First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients},
   url = {http://dx.doi.org/10.1007/s00277-019-03694-y},
   volume = {98},
   year = {2019}
}

TY  - JOUR
ID  - 1611116
AU  - Janíková, Andrea - Chloupková, Renata - Campr, Vit - Klener, Pavel - Hamouzova, Jitka - Belada, David - Prochazka, Vit - Pytlik, Robert - Pirnos, Jan - Duras, Juraj - Mocikova, Heidi - Bortlíček, Zbyněk - Kopalova, Natasa - Mayer, Jiří - Trneny, Marek
PY  - 2019
TI  - First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients
JF  - Annals of hematology
VL  - 98
IS  - 8
SP  - 1961-1972
EP  - 1961-1972
PB  - Springer Verlag
SN  - 09395555
KW  - T cell lymphoma
KW  - Auto-SCT
KW  - Etoposide
KW  - Prognosis
UR  - http://dx.doi.org/10.1007/s00277-019-03694-y
L2  - http://dx.doi.org/10.1007/s00277-019-03694-y
N2  - Peripheral T cell lymphomas (PTLs) have a globally poor prognosis. The CHOP regimen shows insufficient efficacy; first-line consolidation with autologous stem cell transplantation (auto-SCT) is a promising strategy but has never been confirmed by randomized data. We analyzed retrospectively 906 patients diagnosed with PTL between 1999 and 2015. Chemotherapy was given to 862 patients, and 412 of them were <60years. In this subset, we compared induction with CHOP (n=113) vs. CHOEP (n=68) and tested auto-SCT (n=79) vs. no SCT (n=73) in the intent-to-treat analysis. The median age of the whole cohort at diagnosis was 60years (range; 18-91); the median follow-up was 4.3years (range; 0.1-17.8). A shorter overall survival (OS) was associated with the male gender, age >= 60years, stage III/IV, performance status >= 2, bulky tumor >= 10cm, and elevated LDH. CHOEP induction showed a better 5-year PFS (25.0% vs. 32.9%; p.001), and 5-year OS (65.6% vs. 47.6%; p.008) than CHOP. Auto-SCT compared to no SCT brought a 5-year OS of 49.2% vs. 59.5% (p.187). Auto-SCT did not influence the OS in low-risk or low-intermediate risk PTLs. The high-intermediate and high-risk IPIs displayed a worse 5-year OS in auto-SCT arm (17.7% vs.46.2%; p.049); however, 73.9% of the patients never received planned auto-SCT. Our population-based analysis showed the superiority of CHOEP over CHOP in first-line treatment. We confirm the 5-year OS of around 50% in PTLs undergoing auto-SCT. However, the intended auto-SCT could not be given in 73.9% of the high-risk PTLs.
ER  -

JANÍKOVÁ, Andrea, Renata CHLOUPKOVÁ, Vit CAMPR, Pavel KLENER, Jitka HAMOUZOVA, David BELADA, Vit PROCHAZKA, Robert PYTLIK, Jan PIRNOS, Juraj DURAS, Heidi MOCIKOVA, Zbyněk BORTLÍČEK, Natasa KOPALOVA, Jiří MAYER and Marek TRNENY. First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. \textit{Annals of hematology}. New York: Springer Verlag, 2019, vol.~98, No~8, p.~1961-1972. ISSN~0939-5555. Available from: https://dx.doi.org/10.1007/s00277-019-03694-y.

Detailed Information on Publication Record